

TOPICS

ALK and Torii entered into an exclusive license agreement for allergy immunotherapy products in Japan

On January 28, 2011, Torii entered into an exclusive license agreement with ALK to develop and commercialize ALK's house dust mite allergy immunotherapy products for asthma and allergic rhinitis in Japan. The agreement gives Torii exclusive rights for development, marketing and distribution in Japan of ALK's tablet-based immunotherapy product against house dust mite allergy, MITIZAX. The agreement also covers an injection-based immunotherapy product, Alutard, and diagnostic products against house dust mite allergy. Moreover, the agreement includes a research and development collaboration targeting a tablet-based immunotherapy product against Japanese cedar pollen allergy.

Under the agreement, Torii paid ALK an upfront payment of EUR 30 million and will pay up to EUR 30 million in development and market registration milestone payments. After the product is launched, Torii will pay royalties and sales milestones on the net sales of the products.



Torii Senior Executive Director Yuji Kagohashi and ALK Executive Vice President Flemming Pedersen exchange commemorative gifts.

Profile of ALK

Name:	ALK-Abelló A/S
Head office:	Hørsholm, Denmark
Establishment:	1923
President & CEO:	Jens Bager
Net sales:	2,140 million Danish kroner (year ended December 2010)
Employees:	1,694 (December 31, 2010)
Activities:	Development, manufacture and sale of therapeutic, preventive and diagnostic drugs in the allergic disease field
Other information:	Listed on NASDAQ OMX Copenhagen

Hyperkalemia Improvement Agent, KAYEXALATE DRYSYRUP 76% Launched

For Hyperkalemia
KAYEXALATE DRYSYRUP 76%



On February 7, 2011, Torii launched a hyperkalemia improvement agent, KAYEXALATE DRYSYRUP 76% (generic name: sodium polystyrene sulfonate).

KAYEXALATE is a hyperkalemia improvement agent whose active ingredient is sodium polystyrene sulfonate. It lowers serum potassium by exchanging potassium ions in the intestinal tract. KAYEXALATE DRYSYRUP 76% is a low-calorie preparation featuring a refreshing apple flavor, developed as a new dosage form of KAYEXALATE POWDER. It is expected to broaden the range of options for potassium-lowering agents, and to contribute to enhancing the patients' quality of life.

An outline of KAYEXALATE DRYSYRUP 76%

Brand name:	KAYEXALATE DRYSYRUP 76%
Generic name:	Sodium polystyrene sulfonate
Indication:	Hyperkalemia caused by acute and chronic renal failure
Dosage and administrations:	The usual oral dosage for adults is 39.24 g per day (30 g per day as sodium polystyrene sulfonate) divided into 2-3 doses. A single dose is suspended in 50-150 ml of water, and administered orally. The dosage may be adjusted according to symptoms.
Distributed by:	Torii Pharmaceutical Co., Ltd.

What is hyperkalemia?

Hyperkalemia is a condition in which reduced renal function or other factors cause potassium in the blood to reach an elevated level of 5.5mEq/L or higher. Symptoms include numbness of the extremities, paralysis, abdominal pain and diarrhea. There can also be cardiac effects, such as arrhythmia. In severe cases there is a risk of cardiac arrest, and emergency treatment is required.